FDA approves KALYDECO for treatment of eligible infants with cystic fibrosis

This article was originally published here

KALYDECO is already approved in the U.S., Canada and EU for the treatment of CF in patients ages 12 months and older. “Today’s approval for KALYDECO allows physicians

The post FDA approves KALYDECO for treatment of eligible infants with cystic fibrosis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply